DOCSLIB.ORG

Eric John Lavonas, Md, Ms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Eric John Lavonas, Md, Ms ERIC JOHN LAVONAS, MD, MS CURRICULUM VITAE - Abridged Revision date: January 2019 CURRENT POSITION: Emergency physician and medical toxicologist Senior Medical Director, DH Winter Park Medical Center and Alpine Clinic Medical Staff President Denver Health Denver, Colorado, USA BUSINESS ADDRESS: Department of Emergency Medicine Denver Health and Hospital Authority 777 Bannock Street, Mail Code 0108 Denver, Colorado 80204 USA (303) 602-5175 (Office) (303) 602-5184 (Fax) email: [email protected] EDUCATION: Undergraduate Degree: BA Health Care Policy 1988 University of Rochester Rochester, New York Graduate Degree: MD Doctor of Medicine 1992 State University of New York Health Sciences Center Syracuse, New York Degree: MS Clinical Sciences Program (Clinical Research) 2018 University of Colorado – Denver Aurora, Colorado Post-Graduate Emergency Medicine Methodist Hospital of Indiana 1992 – 1995 Residency Indianapolis, Indiana Medical Toxicology Carolinas Medical Center and Carolinas Poison Center 1999 – 2001 Fellowship Charlotte, North Carolina Eric J. Lavonas, MD Page 2 MEDICAL LICENSURE: Indiana 1993 – 2007 Kentucky 1995 – 2000 North Carolina 1999 – 2017 Colorado 2008 – present DEA registration 1993 – present DEA “X” waiver (buprenorphine prescribing) 2018 - present BOARD CERTIFICATON: Emergency Medicine American Board of Emergency Medicine 1996 – present #950606 Initial certification 1996; recertified 2006, 2016 Medical Toxicology American Board of Emergency Medicine 2002 – present #950606 Initial certification 2002; recertified 2012 Undersea and Hyperbaric American Board of Emergency Medicine 2004 - present Medicine #950606 Initial certification 2004; recertified 2014 ACADEMIC APPOINTMENTS: Professor 2016 – present Department of Emergency Medicine University of Colorado School of Medicine Aurora, Colorado MILITARY SERVICE Honorably discharged. Final rank: Captain, Medical Corps 1997 Individual Ready Reserves 1994 - 1997 Brigade Surgeon 1992 – 1994 Captain, Medical Corps Combat Aviation Brigade, 38th Infantry Division US Army National Guard Shelbyville, Indiana Eric J. Lavonas, MD Page 3 Medical Platoon Leader 1989 - 1992 Second Lieutenant, Medical Services Corps Headquarters / Headquarters Company, 42nd Infantry Brigade, 10th Mountain Division US Army National Guard Syracuse, New York COMMITTEE SERVICE International International Liaison Committee on Resuscitation Evidence Reviewer 2018 Evidence Reviewer 2014 – 2015 Member, Advanced Life Support Guidelines Writing Group 2010 Member, Advanced Life Support Task Force 2008 – 2010 Domain Leader, Toxicology Topics 2008 – 2010 Evidence Reviewer 2008 – 2010 Member, Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup 2010 – 2011 Workshop on Antidotes to Highly Toxic Chemical Substances, Pushkin, Russia Member, United States Delegation 2004 Jointly sponsored by the US Department of State, US Department of Health and Human Services, Russian Ministry of Health, and International Science and Technology Center (Moscow) National Member, Project Technical Panel: Impact of Altitude on Carbon Monoxide Alarm 2015 – present Requirements, Fire Protection Research Foundation American Heart Association Opioid Overdose Scientific Statement Writing Group: Senior author 2019 Special Circumstances of Resuscitation: Guidelines Writing Group 2014 – 2015 Chair 2010 Member Advanced Life Support Subcommittee, Emergency Cardiac Care Committee 2011 – 2013 Member Underwriter’s Laboratories / American National Standards Institute Standards Technical Panel 2034 (Carbon Monoxide Alarms) Member, Task Group for Development of Proposed Requirements to Address the 2014 – 2015 Carbon Monoxide Poisoning Hazard Associated with Portable Generators Member, High Altitude Task Group 2011 – 2014 Panel Member 2008 – present Eric J. Lavonas, MD Page 4 American College of Medical Toxicology Abstract Review Chair, Annual Scientific Meeting 2013 – 2015 Chair, Position Statements and Guidelines Committee 2013 – 2015 Member, Program Director’s Committee 2013 – 2015 Member, Board of Directors 2011 – 2015 Co-Chair, Research Committee 2011 – 2014 Chair, Liaison Committee 2010 – 2011 Co-Director, Clinical-Pathologic Correlation (CPC) Case Competition 2006 – 2009 Chair, By-Laws Committee 2004 – 2010 American College of Emergency Physicians Council Alternate Councillor 2012 – 2015 Councillor 2009 – 2011 Toxicology Section Immediate Past-Chair 2009 – 2011 Chair 2007 – 2009 Secretary/Newsletter Editor 2005 – 2007 Clinical Policies Committee Member 2006 – 2012 Spokesman 2006 – present Hyperbaric Medicine Section Immediate Past-Chair 2005 – 2006 Chair 2004 – 2005 Chair-Elect 2003 – 2004 Secretary/Newsletter Editor 2002 – 2003 Delegate to the United States Pharmacopeial (USP) Quinquennial Convention 2000 Air Pollution and Respiratory Health Branch, National Center for Environmental Health, US Centers for Disease Control and Prevention (CDC) Member, Carbon Monoxide Poisoning Reportable Condition Working Group 2011 – present Member, Carbon Monoxide Poisoning Surveillance Working Group 2008 – present American Board of Emergency Medicine Oral Examination Standard-Setting Panel Member 2017 Oral Examiner 2010 – present Representative to the Undersea and Hyperbaric Medicine Examination Committee 2006 – 2009 American Board of Preventive Medicine Representative to the Undersea and Hyperbaric Medicine Examination Committee 2009 – 2010 Consumer Products Safety Commission and PIRE Institute Member, Expert Panel Convened to Improve the Estimates of the Costs of Injuries Due 2009 to Poisoning Eric J. Lavonas, MD Page 5 Diver’s Alert Network Consulting Physician 2000 – 2008 US Food and Drug Administration Ad hoc member (non-voting), Drug Safety and Risk Management Advisory Committee 2013 Regional and Local Data and Research Work Group Colorado Consortium for Prescription Drug Abuse 2013 – 2015 Prevention, Colorado Division of Public Health and Epidemiology, Member Denver Epidemiology Work Group, Denver Office of Drug Strategy, Member 2008 – 2014 University University of Colorado School of Medicine Promotions Committee 2017 - 2020 Hospital and Affiliated Organizations Denver Health and Hospital Authority Provider Credentials and Privileging Committee, Interim Chair 2018 - present Quality, Safety, and Service Improvement Subcommittee of the Board of Directors 2018 - present Director of Psychiatry Search Committee, Member 2018 - present Medical Staff President 2018 – 2020 President-Elect 2017 – 2018 Secretary 2014 – 2016 Member, Medical Staff Executive Committee 2014 – present Medical Necessity Committee Chair 2017 – 2018 Member 2017 - present Medical Operations Council, Member 2016 – 2018 Provider Compensation Committee, Member 2016 – 2018 Joint Strategy Team, Member 2016 Epic implementation team, “Super-User” 2016 Executive Committee for Patient Safety and Quality, Member 2013 – 2014 Graduate Medical Education Committee, Member 2013 – 2015 Physician Compensation Committee, Member 2013 – 2015 Physician Conflict of Interest Committee, Member 2011 Director of Public Health Search Committee, Member 2011 Pharmacy and Therapeutics Committee Chair 2010 – 2016 Member 2008 – present Eric J. Lavonas, MD Page 6 Directors of Service Committee, Member 2010 – 2018 Lean Systems Improvement, “Black Belt” 2010 – present World-Class Contact Center Initiative, Process Lead 2010 Emerging Infectious Disease Committee, Member 2009 Carolinas Medical Center Hyperbaric Oxygen Committee Chair (two terms) 2006 – 2007 2001 – 2004 Member 1999 – 2007 Infection Control Committee, Member 2005 – 2007 Intensive Care Advisory Committee, Member 2004 – 2007 Pediatric Emergency Department Director Search Committee, Chair 2003 – 2004 Hospital Resource Group (system-wide disaster planning), Member 2001 – 2007 Disaster Preparedness Subcommittee, Metrolina Trauma Advisory Committee, Member 2005 – 2007 Member, Carbon Monoxide Poisoning Task Force, Mecklenburg County Dept of Health 2000 – 2007 Mecklenburg County Advanced Local Emergency Response (ALERT) Team, Physician 2000 – 2007 Gennesaret Free Clinic, Indianapolis, Volunteer Physician 1995 - 1998 Editorial Board Member Journal of Medical Toxicology 2014 – present HONORS AND AWARDS Outstanding Volunteer Service 2018 American College of Medical Toxicology Denver Health Operational Excellence Awards 2017 First Place: Adult Urgent Care Center: Improving on What We’re Measuring Third Place: Single Point Investigators Outstanding Contribution to Medical Toxicology Research Award 2017 American College of Medical Toxicology Denver Health Pillar Awards Patient Safety: Development of On-Line Provider Directory 2017 Financial Vitality: Largest Increase in Departmental Charges While Maintaining Cost 2016 Design and Implementation of Ebola Preparedness Plan 2015 Patient Safety: Active Participation and Response to Patient Safety Events 2015 Design and Implementation of the Severe Alcohol Withdrawal Protocol 2015 Eric J. Lavonas, MD Page 7 Denver Health S.T.A.R. Awards Pharmacy Efficiency Project: Savings of $84,000/month 2015 Excellent Support for Pharmacovigilance Program 2013 Innovative Support to NurseLine; Expanded Protocol Prescribing Program 2013 Leadership in Buprenorphine Safety Projects 2012 Design and Implementation of Emergency Department Pharmacy Specialist Program 2010 Patient Advocate Award 2014 Denver Residency in Emergency Medicine Black Belt Awards (Financial Savings) More than Double Goal 2010, 2012 More than Quadruple Goal ($117,602) 2011 Black Belt 2010 Denver Health Lean Systems Improvement Fellow 2009 American Academy of
Load more

Recommended publications
  • Ergot Alkaloids Mycotoxins in Cereals and Cereal-Derived Food Products: Characteristics, Toxicity, Prevalence, and Control Strategies
    agronomy Review Ergot Alkaloids Mycotoxins in Cereals and Cereal-Derived Food Products: Characteristics, Toxicity, Prevalence, and Control Strategies Sofia Agriopoulou Department of Food Science and Technology, University of the Peloponnese, Antikalamos, 24100 Kalamata, Greece; [email protected]; Tel.: +30-27210-45271 Abstract: Ergot alkaloids (EAs) are a group of mycotoxins that are mainly produced from the plant pathogen Claviceps. Claviceps purpurea is one of the most important species, being a major producer of EAs that infect more than 400 species of monocotyledonous plants. Rye, barley, wheat, millet, oats, and triticale are the main crops affected by EAs, with rye having the highest rates of fungal infection. The 12 major EAs are ergometrine (Em), ergotamine (Et), ergocristine (Ecr), ergokryptine (Ekr), ergosine (Es), and ergocornine (Eco) and their epimers ergotaminine (Etn), egometrinine (Emn), egocristinine (Ecrn), ergokryptinine (Ekrn), ergocroninine (Econ), and ergosinine (Esn). Given that many food products are based on cereals (such as bread, pasta, cookies, baby food, and confectionery), the surveillance of these toxic substances is imperative. Although acute mycotoxicosis by EAs is rare, EAs remain a source of concern for human and animal health as food contamination by EAs has recently increased. Environmental conditions, such as low temperatures and humid weather before and during flowering, influence contamination agricultural products by EAs, contributing to the Citation: Agriopoulou, S. Ergot Alkaloids Mycotoxins in Cereals and appearance of outbreak after the consumption of contaminated products. The present work aims to Cereal-Derived Food Products: present the recent advances in the occurrence of EAs in some food products with emphasis mainly Characteristics, Toxicity, Prevalence, on grains and grain-based products, as well as their toxicity and control strategies.
    [Show full text]
  • Snake Bite Protocol
    Lavonas et al. BMC Emergency Medicine 2011, 11:2 Page 4 of 15 http://www.biomedcentral.com/1471-227X/11/2 and other Rocky Mountain Poison and Drug Center treatment of patients bitten by coral snakes (family Ela- staff. The antivenom manufacturer provided funding pidae), nor by snakes that are not indigenous to the US. support. Sponsor representatives were not present dur- At the time this algorithm was developed, the only ing the webinar or panel discussions. Sponsor represen- antivenom commercially available for the treatment of tatives reviewed the final manuscript before publication pit viper envenomation in the US is Crotalidae Polyva- ® for the sole purpose of identifying proprietary informa- lent Immune Fab (ovine) (CroFab , Protherics, Nash- tion. No modifications of the manuscript were requested ville, TN). All treatment recommendations and dosing by the manufacturer. apply to this antivenom. This algorithm does not con- sider treatment with whole IgG antivenom (Antivenin Results (Crotalidae) Polyvalent, equine origin (Wyeth-Ayerst, Final unified treatment algorithm Marietta, Pennsylvania, USA)), because production of The unified treatment algorithm is shown in Figure 1. that antivenom has been discontinued and all extant The final version was endorsed unanimously. Specific lots have expired. This antivenom also does not consider considerations endorsed by the panelists are as follows: treatment with other antivenom products under devel- opment. Because the panel members are all hospital- Role of the unified treatment algorithm
    [Show full text]
  • Approach to the Poisoned Patient
    PED-1407 Chocolate to Crystal Methamphetamine to the Cinnamon Challenge - Emergency Approach to the Intoxicated Child BLS 08 / ALS 75 / 1.5 CEU Target Audience: All Pediatric and adolescent ingestions are common reasons for 911 dispatches and emergency department visits. With greater availability of medications and drugs, healthcare professionals need to stay sharp on current trends in medical toxicology. This lecture examines mind altering substances, initial prehospital approach to toxicology and stabilization for transport, poison control center resources, and ultimate emergency department and intensive care management. Pediatric Toxicology Dr. James Burhop Pediatric Emergency Medicine Children’s Hospital of the Kings Daughters Objectives • Epidemiology • History of Poisoning • Review initial assessment of the child with a possible ingestion • General management principles for toxic exposures • Case Based (12 common pediatric cases) • Emerging drugs of abuse • Cathinones, Synthetics, Salvia, Maxy/MCAT, 25I, Kratom Epidemiology • 55 Poison Centers serving 295 million people • 2.3 million exposures in 2011 – 39% are children younger than 3 years – 52% in children younger than 6 years • 1-800-222-1222 2011 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System Introduction • 95% decline in the number of pediatric poisoning deaths since 1960 – child resistant packaging – heightened parental awareness – more sophisticated interventions – poison control centers Epidemiology • Unintentional (1-2
    [Show full text]
  • The Notification of Injuries from Hazardous Substances
    The Notification of Injuries from Hazardous Substances Draft Guidelines and Reference Material for Public Health Services To be used to assist in a pilot study from July – December 2001 April 2001 Jeff Fowles, Ph.D. Prepared by the Institute of Environmental Science and Research, Limited Under contract by the New Zealand Ministry of Health DISCLAIMER This report or document ("the Report") is given by the Institute of Environmental Science and Research Limited ("ESR") solely for the benefit of the Ministry of Health, Public Health Service Providers and other Third Party Beneficiaries as defined in the Contract between ESR and the Ministry of Health, and is strictly subject to the conditions laid out in that Contract. Neither ESR nor any of its employees makes any warranty, express or implied, or assumes any legal liability or responsibility for use of the Report or its contents by any other person or organisation. Guidelines for the Notification of Injuries from Hazardous Substances April 2001 Acknowledgements The author wishes to thank Dr Michael Bates and Melissa Perks (ESR), Sally Gilbert and Helen Saba (Ministry of Health), Dr Donald Campbell (Midcentral Health), Dr Deborah Read (ERMANZ), and Dr Nerida Smith (National Poisons Centre) for useful contributions and helpful suggestions on the construction of these guidelines. Guidelines for the Notification of Injuries from Hazardous Substances April 2001 TABLE OF CONTENTS SUMMARY ........................................................................................................................1
    [Show full text]
  • Hallucinogens: a Cause of Convulsive Ergot Psychoses
    Loma Linda University TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works Loma Linda University Electronic Theses, Dissertations & Projects 6-1976 Hallucinogens: a Cause of Convulsive Ergot Psychoses Sylvia Dahl Winters Follow this and additional works at: https://scholarsrepository.llu.edu/etd Part of the Psychiatry Commons Recommended Citation Winters, Sylvia Dahl, "Hallucinogens: a Cause of Convulsive Ergot Psychoses" (1976). Loma Linda University Electronic Theses, Dissertations & Projects. 976. https://scholarsrepository.llu.edu/etd/976 This Thesis is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. For more information, please contact [email protected]. ABSTRACT HALLUCINOGENS: A CAUSE OF CONVULSIVE ERGOT PSYCHOSES By Sylvia Dahl Winters Ergotism with vasoconstriction and gangrene has been reported through the centuries. Less well publicized are the cases of psychoses associated with convulsive ergotism. Lysergic acid amide a powerful hallucinogen having one.-tenth the hallucinogenic activity of LSD-25 is produced by natural sources. This article attempts to show that convulsive ergot psychoses are mixed psychoses caused by lysergic acid amide or similar hallucinogens combined with nervous system
    [Show full text]
  • 615.9Barref.Pdf
    INDEX Abortifacient, abortifacients bees, wasps, and ants ginkgo, 492 aconite, 737 epinephrine, 963 ginseng, 500 barbados nut, 829 blister beetles goldenseal blister beetles, 972 cantharidin, 974 berberine, 506 blue cohosh, 395 buckeye hawthorn, 512 camphor, 407, 408 ~-escin, 884 hypericum extract, 602-603 cantharides, 974 calamus inky cap and coprine toxicity cantharidin, 974 ~-asarone, 405 coprine, 295 colocynth, 443 camphor, 409-411 ethanol, 296 common oleander, 847, 850 cascara, 416-417 isoxazole-containing mushrooms dogbane, 849-850 catechols, 682 and pantherina syndrome, mistletoe, 794 castor bean 298-302 nutmeg, 67 ricin, 719, 721 jequirity bean and abrin, oduvan, 755 colchicine, 694-896, 698 730-731 pennyroyal, 563-565 clostridium perfringens, 115 jellyfish, 1088 pine thistle, 515 comfrey and other pyrrolizidine­ Jimsonweed and other belladonna rue, 579 containing plants alkaloids, 779, 781 slangkop, Burke's, red, Transvaal, pyrrolizidine alkaloids, 453 jin bu huan and 857 cyanogenic foods tetrahydropalmatine, 519 tansy, 614 amygdalin, 48 kaffir lily turpentine, 667 cyanogenic glycosides, 45 lycorine,711 yarrow, 624-625 prunasin, 48 kava, 528 yellow bird-of-paradise, 749 daffodils and other emetic bulbs Laetrile", 763 yellow oleander, 854 galanthamine, 704 lavender, 534 yew, 899 dogbane family and cardenolides licorice Abrin,729-731 common oleander, 849 glycyrrhetinic acid, 540 camphor yellow oleander, 855-856 limonene, 639 cinnamomin, 409 domoic acid, 214 rna huang ricin, 409, 723, 730 ephedra alkaloids, 547 ephedra alkaloids, 548 Absorption, xvii erythrosine, 29 ephedrine, 547, 549 aloe vera, 380 garlic mayapple amatoxin-containing mushrooms S-allyl cysteine, 473 podophyllotoxin, 789 amatoxin poisoning, 273-275, gastrointestinal viruses milk thistle 279 viral gastroenteritis, 205 silibinin, 555 aspartame, 24 ginger, 485 mistletoe, 793 Medical Toxicology ofNatural Substances, by Donald G.
    [Show full text]
  • Snake Bite Prevention What to Do If You Are Bitten
    SNAKE BITE PREVENTION It has been estimated that 7,000–8,000 people per year are bitten by venomous snakes in the United States, and for around half a dozen people, these bites are fatal. In 2015, poison centers managed over 3,000 cases of snake and other reptile bites during the summer months alone. Approximately 80% of these poison center calls originated from hospitals and other health care facilities. Venomous snakes found in the U.S. include rattlesnakes, copperheads, cottonmouths/water moccasins, and coral snakes. They can be especially dangerous to outdoor workers or people spending more time outside during the warmer months of the year. Most snakebites occur when people accidentally step on or come across a snake, frightening it and causing it to bite defensively. However, by taking extra precaution in snake-prone environments, many of these bites are preventable by using the following snakebite prevention tips: Avoid surprise encounters with snakes: Snakes tend to be active at night and in warm weather. They also tend to hide in places where they are not readily visible, so stay away from tall grass, piles of leaves, rocks, and brush, and avoid climbing on rocks or piles of wood where a snake may be hiding. When moving through tall grass or weeds, poke at the ground in front of you with a long stick to scare away snakes. Watch where you step and where you sit when outdoors. Shine a flashlight on your path when walking outside at night. Wear protective clothing: Wear loose, long pants and high, thick leather or rubber boots when spending time in places where snakes may be hiding.
    [Show full text]
  • Bites and Stings [Poisonous Animals and Plants]
    Poisonous animals and plants Dr Tim Healing Dip.Clin.Micro, DMCC, CBIOL, FZS, FRSB Course Director, Course in Conflict and Catastrophe Medicine Worshipful Society of Apothecaries of London Faculty of Conflict and Catastrophe Medicine Animal and plant toxins • In most instances the numbers of people affected will be small • There are a few instances where larger numbers may be involved – mainly due to food-borne toxins Poisonous species (N.B. Venomous species use poisons for attack, poisonous animals and plants for passive defence) Venomous and poisonous animals – Reptiles (snakes) – Amphibians (dart frogs) – Arthropods (scorpions, spiders, wasps, bees, centipedes) – Aquatic animals (fish, jellyfish, octopi) Poisonous plants – Contact stinging (nettles, poison ivy, algae) – Poisonous by ingestion (fungi, berries of some plants) – Some algae Snakes Venomous Snakes • About 600 species of snake are venomous (ca. 25% of all snake species). Four main groups: – Elapidae (elapids). Mambas, Cobras, King cobras, Kraits, Taipans, Sea snakes, Brown snakes, Coral snakes. – Viperidae (viperids). True vipers and pit vipers (including Rattlesnakes, Copperheads and Cottonmouths) – Colubridae (colubrids). Mostly harmless, but includes the Boomslang – Atractaspididae (atractaspidids). Burrowing asps, Mole vipers, Stiletto snakes. Geographical distribution • Elapidae: – On land, worldwide in tropical and subtropical regions, except in Europe. – Sea snakes occur in the Indian Ocean and the Pacific • Viperidae: – The Americas, Africa and Eurasia. • Boomslangs
    [Show full text]
  • Venom Week 2012 4Th International Scientific Symposium on All Things Venomous
    17th World Congress of the International Society on Toxinology Animal, Plant and Microbial Toxins & Venom Week 2012 4th International Scientific Symposium on All Things Venomous Honolulu, Hawaii, USA, July 8 – 13, 2012 1 Table of Contents Section Page Introduction 01 Scientific Organizing Committee 02 Local Organizing Committee / Sponsors / Co-Chairs 02 Welcome Messages 04 Governor’s Proclamation 08 Meeting Program 10 Sunday 13 Monday 15 Tuesday 20 Wednesday 26 Thursday 30 Friday 36 Poster Session I 41 Poster Session II 47 Supplemental program material 54 Additional Abstracts (#298 – #344) 61 International Society on Thrombosis & Haemostasis 99 2 Introduction Welcome to the 17th World Congress of the International Society on Toxinology (IST), held jointly with Venom Week 2012, 4th International Scientific Symposium on All Things Venomous, in Honolulu, Hawaii, USA, July 8 – 13, 2012. This is a supplement to the special issue of Toxicon. It contains the abstracts that were submitted too late for inclusion there, as well as a complete program agenda of the meeting, as well as other materials. At the time of this printing, we had 344 scientific abstracts scheduled for presentation and over 300 attendees from all over the planet. The World Congress of IST is held every three years, most recently in Recife, Brazil in March 2009. The IST World Congress is the primary international meeting bringing together scientists and physicians from around the world to discuss the most recent advances in the structure and function of natural toxins occurring in venomous animals, plants, or microorganisms, in medical, public health, and policy approaches to prevent or treat envenomations, and in the development of new toxin-derived drugs.
    [Show full text]
  • Long-Term Effects of Snake Envenoming
    toxins Review Long-Term Effects of Snake Envenoming Subodha Waiddyanatha 1,2, Anjana Silva 1,2 , Sisira Siribaddana 1 and Geoffrey K. Isbister 2,3,* 1 Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura 50008, Sri Lanka; [email protected] (S.W.); [email protected] (A.S.); [email protected] (S.S.) 2 South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Peradeniya 20400, Sri Lanka 3 Clinical Toxicology Research Group, University of Newcastle, Callaghan, NSW 2308, Australia * Correspondence: [email protected] or [email protected]; Tel.: +612-4921-1211 Received: 14 March 2019; Accepted: 29 March 2019; Published: 31 March 2019 Abstract: Long-term effects of envenoming compromise the quality of life of the survivors of snakebite. We searched MEDLINE (from 1946) and EMBASE (from 1947) until October 2018 for clinical literature on the long-term effects of snake envenoming using different combinations of search terms. We classified conditions that last or appear more than six weeks following envenoming as long term or delayed effects of envenoming. Of 257 records identified, 51 articles describe the long-term effects of snake envenoming and were reviewed. Disability due to amputations, deformities, contracture formation, and chronic ulceration, rarely with malignant change, have resulted from local necrosis due to bites mainly from African and Asian cobras, and Central and South American Pit-vipers. Progression of acute kidney injury into chronic renal failure in Russell’s viper bites has been reported in several studies from India and Sri Lanka. Neuromuscular toxicity does not appear to result in long-term effects.
    [Show full text]
  • Snakebite and Spiderbite Clinical Management Guidelines 2013
    Guideline Ministry of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/ space space Snakebite and Spiderbite Clinical Management Guidelines 2013 - Third Edition space Document Number GL2014_005 Publication date 17-Mar-2014 Functional Sub group Clinical/ Patient Services - Critical care Clinical/ Patient Services - Medical Treatment Summary Revised clinical resource document which provides information and advise on the management of patients with actual or suspected snakebite or spiderbite, and the appropriate levels, type and location of stored antivenom in NSW health facilities. These are clinical guidelines for best clinical practice which are not mandatory but do provide essential clinical support. Replaces Doc. No. Snakebite & Spiderbite Clinical Management Guidelines 2007 - NSW [GL2007_006] Author Branch Agency for Clinical Innovation Branch contact Agency for Clinical Innovation 9464 4674 Applies to Local Health Districts, Board Governed Statutory Health Corporations, Chief Executive Governed Statutory Health Corporations, Specialty Network Governed Statutory Health Corporations, Affiliated Health Organisations, Community Health Centres, Government Medical Officers, NSW Ambulance Service, Ministry of Health, Private Hospitals and Day Procedure Centres, Public Health Units, Public Hospitals Audience Clinicial Nursing, Medical, Allied Health Staff, Administration, ED, Intensive Care Units Distributed to Public Health System, Divisions of General Practice, Government Medical Officers, Ministry of Health, Private Hospitals and Day Procedure Centres, Tertiary Education Institutes Review date 17-Mar-2019 Policy Manual Patient Matters File No. 12/4133 Status Active Director-General FIVE Spiderbite Guidelines for Assessment and Management Introduction Red-back spider envenoming or latrodectism is Specific features of funnel-web and red back bite are characterised by severe local or regional pain associated discussed below.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]